Showing results (231-240 of 274) with videos related to

Sort By:
Pageof 28
Current Opinion in Behavioral Sciences|May 4, 2019
The interplay among psychological distress, the immune system, and brain tumor patient outcomesSebastian Otto-Meyer, Jan Lumibao, Eugene Kim, et al.
The Journal of Clinical Endocrinology and Metabolism|February 25, 2005
Hip fracture in women without osteoporosisStacey A Wainwright, Lynn M Marshall, Kristine E Ensrud, et al.
Pigment Cell & Melanoma Research|February 24, 2010
Reduced skin homing by functional Treg in vitiligoJared Klarquist, Cecele J Denman, Claudia Hernandez, et al.
Behavior Genetics|May 7, 2009
Genetic covariation between theAuthor Recognition Test and reading and verbal abilities: what can we learn from the analysis of high performance?Nicolas W Martin, Narelle K Hansell, Mark A Wainwright, et al.
Brain, Behavior, and Immunity|February 10, 2017
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastomaLijie Zhai, Erik Ladomersky, Carlos R Dostal, et al.
Cancer Gene Therapy|January 18, 2014
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant gliomaB Thaci, A U Ahmed, I V Ulasov, et al.
Brain, Behavior, & Immunity - Health|March 20, 2020
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitorsSebastian Otto-Meyer, Rian DeFaccio, Corey Dussold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 31, 2015
Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant GliomaMahua Dey, Alan L Chang, Jason Miska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2014
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumorsDerek A Wainwright, Alan L Chang, Mahua Dey, et al.
Oncoimmunology|February 7, 2019
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)Lijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Pageof 28